Article
Effect of PPADS on achondroplasic chondrocytes: inhibition of FGF receptor type 3 over-activity.
European journal of pharmacology - 14 Apr 2008
Guzmán-Aránguez Ana, Crooke Almudena, Yayon Avner, Pintor Jesús
Abstract excerpt
Achondroplasia, results from a mutation in the FGF receptor type 3, leading to receptor hyperactivation and subsequent amplification of FGF receptor type 3 signals. We have tested the ability of pyridoxal-5'-phosphate-6-azophenyl-2', 4'-disulfonate (PPADS) to decrease the overactivation and signalling of FGF receptor type 3 in achondroplasic chondrocytes. PPADS reduced the tyrosine phosphorylation of FGF receptor...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.